CNBX Pharmaceuticals Inc.
CNBX
$0.0024
$0.000420.00%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 40.60K | 130.00K | 230.00K | 540.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 40.60K | 130.00K | 230.00K | 540.20K |
| Cost of Revenue | -- | 6.20K | 6.20K | 6.20K | 6.20K |
| Gross Profit | 0.00 | 34.40K | 123.80K | 223.80K | 534.00K |
| SG&A Expenses | 337.40K | 406.30K | 518.40K | 560.20K | 670.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 306.30K | 488.70K | 713.20K | 922.20K | 1.25M |
| Operating Income | -306.30K | -448.00K | -583.10K | -692.10K | -712.90K |
| Income Before Tax | -295.40K | -551.10K | -695.20K | -1.21M | -1.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.30 | -0.55 | -0.70 | -1.21 | -1.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -295.40K | -551.10K | -695.20K | -1.21M | -1.23M |
| EBIT | -306.30K | -448.00K | -583.10K | -692.10K | -712.90K |
| EBITDA | -270.30K | -397.20K | -510.80K | -581.30K | -562.10K |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.05 | -0.06 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.05 | -0.06 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
| Average Basic Shares Outstanding | 125.42M | 124.31M | 120.96M | 113.07M | 91.22M |
| Average Diluted Shares Outstanding | 125.42M | 124.31M | 120.96M | 113.07M | 91.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |